Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injections of NNC0582-0001 in Healthy Adults
Latest Information Update: 06 Mar 2025
Price :
$35 *
At a glance
- Drugs NNC0582 0001 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 25 Feb 2025 Planned End Date changed from 30 Sep 2025 to 25 Oct 2025.
- 25 Feb 2025 Planned primary completion date changed from 30 Sep 2025 to 25 Oct 2025.
- 25 Feb 2025 Status changed from recruiting to active, no longer recruiting.